CN110573525A - 用抗tslp抗体治疗哮喘 - Google Patents

用抗tslp抗体治疗哮喘 Download PDF

Info

Publication number
CN110573525A
CN110573525A CN201880026131.3A CN201880026131A CN110573525A CN 110573525 A CN110573525 A CN 110573525A CN 201880026131 A CN201880026131 A CN 201880026131A CN 110573525 A CN110573525 A CN 110573525A
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
ser
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880026131.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·帕尼斯
J·格里菲思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Midi Muni Co Ltd
Amgen Inc
MedImmune LLC
Original Assignee
Midi Muni Co Ltd
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midi Muni Co Ltd, Amgen Inc filed Critical Midi Muni Co Ltd
Publication of CN110573525A publication Critical patent/CN110573525A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880026131.3A 2017-04-12 2018-04-12 用抗tslp抗体治疗哮喘 Pending CN110573525A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US62/484,864 2017-04-12
US201762553575P 2017-09-01 2017-09-01
US201762553477P 2017-09-01 2017-09-01
US62/553,477 2017-09-01
US62/553,575 2017-09-01
PCT/US2018/027271 WO2018191479A1 (en) 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody

Publications (1)

Publication Number Publication Date
CN110573525A true CN110573525A (zh) 2019-12-13

Family

ID=62092313

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880026131.3A Pending CN110573525A (zh) 2017-04-12 2018-04-12 用抗tslp抗体治疗哮喘

Country Status (21)

Country Link
US (3) US10828365B2 (enExample)
EP (1) EP3609917A1 (enExample)
JP (4) JP7330896B2 (enExample)
KR (2) KR20240070727A (enExample)
CN (1) CN110573525A (enExample)
AU (2) AU2018253118B2 (enExample)
BR (1) BR112019021482A2 (enExample)
CA (1) CA3059364A1 (enExample)
CL (1) CL2019002897A1 (enExample)
CO (1) CO2019011462A2 (enExample)
IL (1) IL269791B (enExample)
JO (1) JOP20190243A1 (enExample)
MX (1) MX2019012158A (enExample)
MY (1) MY207509A (enExample)
PE (1) PE20200484A1 (enExample)
PH (1) PH12019502331A1 (enExample)
SG (1) SG11201909322VA (enExample)
TN (1) TN2019000289A1 (enExample)
TW (2) TWI856945B (enExample)
UY (1) UY37676A (enExample)
WO (1) WO2018191479A1 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
CN113501878A (zh) * 2021-02-03 2021-10-15 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN113683694A (zh) * 2021-09-03 2021-11-23 江苏荃信生物医药有限公司 一种抗人tslp单克隆抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN114853888A (zh) * 2021-02-05 2022-08-05 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
WO2022184074A1 (zh) * 2021-03-03 2022-09-09 正大天晴药业集团股份有限公司 含抗tslp抗体的药物组合物
CN116217724A (zh) * 2021-12-02 2023-06-06 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
CN117551195A (zh) * 2024-01-12 2024-02-13 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3347377B1 (en) * 2015-09-09 2021-02-17 Novartis AG Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
TW202110882A (zh) 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
AU2020311432A1 (en) * 2019-07-11 2022-02-03 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合ｔｓｌｐ及びその使用
RS66646B1 (sr) * 2019-10-28 2025-04-30 Medimmune Ltd Formulacije suvog praška vezujućih antitela za timusni stromalni limfopoetin (tslp) i postupci njihove upotrebe
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
US20220363781A1 (en) * 2019-12-13 2022-11-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN115279404A (zh) * 2020-02-13 2022-11-01 安进公司 人抗tslp抗体的配制品及治疗炎性疾病的方法
WO2021163588A1 (en) * 2020-02-13 2021-08-19 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
MX2022010120A (es) * 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
KR20230172508A (ko) * 2021-04-19 2023-12-22 메디뮨 리미티드 안정성이 개선된 항-tslp fab
BR112023022041A2 (pt) 2021-04-23 2023-12-26 Amgen Inc Anticorpos anti-tslp modificados
EP4326766A1 (en) 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
TW202523697A (zh) * 2023-08-25 2025-06-16 美商普羅特歐拉吉克適美國公司 抗ｔｓｌｐ抗體構築體及其用途
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090238823A1 (en) * 2007-09-10 2009-09-24 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2016023019A2 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
US20170066823A1 (en) * 2015-09-09 2017-03-09 Matthew John EDWARDS Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
US20170067108A1 (en) * 2013-10-23 2017-03-09 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
WO2016142426A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090238823A1 (en) * 2007-09-10 2009-09-24 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
CN101809035A (zh) * 2007-09-10 2010-08-18 安美基公司 能结合胸腺基质淋巴细胞生成素的抗原结合蛋白
US20170067108A1 (en) * 2013-10-23 2017-03-09 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
WO2016023019A2 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
US20170066823A1 (en) * 2015-09-09 2017-03-09 Matthew John EDWARDS Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GAIL M GAUVREAU等: "Effects of an anti-TSLP antibody on allergen-induced asthmatic responses", 《N ENGL J MED》 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878A (zh) * 2021-02-03 2021-10-15 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
CN114853888A (zh) * 2021-02-05 2022-08-05 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
WO2022184074A1 (zh) * 2021-03-03 2022-09-09 正大天晴药业集团股份有限公司 含抗tslp抗体的药物组合物
CN116897053A (zh) * 2021-03-03 2023-10-17 正大天晴药业集团股份有限公司 含抗tslp抗体的药物组合物
CN113683694A (zh) * 2021-09-03 2021-11-23 江苏荃信生物医药有限公司 一种抗人tslp单克隆抗体及其应用
US12378309B2 (en) 2021-09-03 2025-08-05 Qyuns Therapeutics Co., Ltd. Anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and use thereof to treat disease
CN116217724A (zh) * 2021-12-02 2023-06-06 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN116217724B (zh) * 2021-12-02 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
CN117551195A (zh) * 2024-01-12 2024-02-13 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用

Also Published As

Publication number Publication date
KR20190140956A (ko) 2019-12-20
TW201838652A (zh) 2018-11-01
JP2024150751A (ja) 2024-10-23
AU2018253118A1 (en) 2019-10-24
IL269791B (en) 2022-07-01
SG11201909322VA (en) 2019-11-28
CL2019002897A1 (es) 2020-03-06
TWI856945B (zh) 2024-10-01
KR102666879B1 (ko) 2024-05-23
KR20240070727A (ko) 2024-05-21
US10828365B2 (en) 2020-11-10
US20250032608A1 (en) 2025-01-30
US20210052726A1 (en) 2021-02-25
MX2019012158A (es) 2019-12-16
EP3609917A1 (en) 2020-02-19
CA3059364A1 (en) 2018-10-18
TW202523688A (zh) 2025-06-16
BR112019021482A2 (pt) 2020-05-12
AU2025204735A1 (en) 2025-07-17
PH12019502331A1 (en) 2020-09-28
CO2019011462A2 (es) 2019-10-31
AU2018253118B2 (en) 2025-04-10
TN2019000289A1 (en) 2021-05-07
JOP20190243A1 (ar) 2019-10-13
JP2023099233A (ja) 2023-07-11
IL269791A (en) 2019-11-28
PE20200484A1 (es) 2020-03-03
JP7330896B2 (ja) 2023-08-22
UY37676A (es) 2018-10-31
JP2025170430A (ja) 2025-11-18
US20180296669A1 (en) 2018-10-18
WO2018191479A1 (en) 2018-10-18
MY207509A (en) 2025-02-28
JP2020516647A (ja) 2020-06-11

Similar Documents

Publication Publication Date Title
US20250032608A1 (en) Treatment of asthma with anti-tsl p antibody
EP2627673B1 (en) Therapies for improving pulmonary function
KR20230175245A (ko) 변형된 항-tslp 항체
CN115151276A (zh) 人抗tslp抗体的配制品及其使用方法
JP2013525310A (ja) Ｃｏｐｄ増悪を治療するための組成物および方法
US20230073888A1 (en) Treatment of atopic dermatitis with anti-tslp antibody
US20240117058A1 (en) Treatment of cytokine release syndrome with gm-csf antagonists
US20240360210A1 (en) Use of an il-18 antagonist for treating and/or prevention of atopic dermatitis or a related condition
AU2024274293A1 (en) Treatment of corticosteroid dependent asthma with anti-tslp antibody
AU2024274293A9 (en) Treatment of corticosteroid dependent asthma with anti-tslp antibody
KR20250140101A (ko) 항-tslp 항체를 이용한 만성 비부비동염의 치료
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
WO2025147632A1 (en) Treatment of chronic obstructive pulmonary disease with anti-tslp antibody
WO2025221247A1 (en) Treatment of eosinophilic esophagitis with anti-tslp antibody
HK1188603A (en) Therapies for improving pulmonary function
HK1188603B (en) Therapies for improving pulmonary function

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination